GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026
PR Newswire•05/10/2026•16:01 ET
0
Key Highlights
- ➤GRAIL (GRAL) will present eight NHS-Galleri and PATHFINDER 2 abstracts at EDCC and ESMO.
- ➤NHS-Galleri data will assess preclinical detection windows and compatibility with annual MCED screening.
- ➤PATHFINDER 2 data will evaluate Galleri performance across self-reported racial and ethnic groups.
- ➤Annual Galleri screening was associated with fewer cancer diagnoses in emergency settings.
- ➤ESMO presentation will report efficiency and safety of Cancer Signal Origin-guided diagnostic workups.
Expert Statements
Josh Ofman, CEO of GRAIL
“Ongoing analyses of PATHFINDER 2 and NHS-Galleri trial data continue to strengthen the evidence for integrating multi-cancer early detection into routine care.”
Josh Ofman, CEO of GRAIL
“Across large, diverse populations, these data continue to demonstrate Galleri's strong performance and favorable safety profile, and reinforce its potential to fundamentally improve how we screen for cancer by finding more cancers, before symptoms are present, in early stages, when there is the greatest opportunity for curative intent treatment.”
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026 PR Newswire
GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection
Get started
Create a free account to read the full story.